The Valley Desk

NCT01208051 · Interventional trial

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Overall registry status Completed

Phase 1 · Phase 2

Conditions Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov